Literature DB >> 16676173

Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration.

Petra A Thürmann1, Jacek Szymanski, Steffen Haffner, Ute Tenter, Frank Grieger, C Sonnenburg.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16676173     DOI： 10.1007/s00228-006-0137-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

Review 1.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

2.  Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation.

Authors:  P A Thürmann; C Sonnenburg-Chatzopoulos; R Lissner
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation.

Authors:  G J Burbach; U Bienzle; R Neuhaus; U Hopf; W G Metzger; J Pratschke; P Neuhaus
Journal:  Transplantation       Date:  1997-02-15       Impact factor: 4.939

4.  Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma.

Authors:  P A Thürmann; C Sonnenburg; K Valentová; E Gregora; F Freischläger; R Lissner
Journal:  Eur J Clin Pharmacol       Date:  2001-06       Impact factor: 2.953

5.  A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection.

Authors:  N Partovi; M W Guy; M H Ensom; M A Noble; E M Yoshida
Journal:  Am J Transplant       Date:  2001-05       Impact factor: 8.086

6.  Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.

Authors:  J S Markowitz; P Martin; A J Conrad; J F Markmann; P Seu; H Yersiz; J A Goss; P Schmidt; A Pakrasi; L Artinian; N G Murray; D K Imagawa; C Holt; L I Goldstein; R Stribling; R W Busuttil
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

7.  Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation.

Authors:  Steven-Huy Han; Paul Martin; Marc Edelstein; Rena Hu; Gregg Kunder; Curtis Holt; Sammy Saab; Francisco Durazo; Leonard Goldstein; Douglas Farmer; Rafik M Ghobrial; Ronald W Busuttil
Journal:  Liver Transpl       Date:  2003-02       Impact factor: 5.799

8.  Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs.

Authors:  A Gardulf; V Andersen; J Björkander; D Ericson; S S Frøland; R Gustafson; L Hammarström; M B Jacobsen; E Jonsson; G Möller
Journal:  Lancet       Date:  1995-02-11       Impact factor: 79.321
  8 in total
  2 in total

Review 1.  The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation.

Authors:  Arianeb Mehrabi; Majid Esmaeilzadeh; Hamidreza Fonouni; Mohammadreza Hafezi; Nuh N Rahbari; Mohammad Golriz; Ali Majlesara; Morva Tahmasbi Rad; Mahmoud Sadeghi; Jan Schmidt; Tom M Ganten
Journal:  Langenbecks Arch Surg       Date:  2011-05-02       Impact factor: 3.445

Review 2.  The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.

Authors:  Jing-Fen Jin; Ling-Ling Zhu; Meng Chen; Hui-Min Xu; Hua-Fen Wang; Xiu-Qin Feng; Xiu-Ping Zhu; Quan Zhou
Journal:  Patient Prefer Adherence       Date:  2015-07-02       Impact factor: 2.711
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.